Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Observer-blinded, Randomized, Active-controlled Study to Examine the Immunogenicity and Safety of Rotarix® and RV3-BB When Co-administered/Boosted With Trivalent P2-VP8 Subunit Rotavirus Vaccine Candidate in Healthy Infants in South Africa

NCT04344054 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT04344054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04344054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Observer-blinded, Randomized, Active-controlled Study to Examine the Immunogenicity and Safety of Rotarix® and RV3-BB When Co-administered/Boosted With Trivalent P2-VP8 Subunit Rotavirus Vaccine Candidate in Healthy Infants in South Africa
Lead sponsor
PATH
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2021
Completion date
September 9, 2022
Enrollment
850 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rotavirus vaccine